The renin-angiotensin system is involved in hypertension and, thus, in cardiac and vascular
injury. In general, angiotensin II is considered as the main mediator of this system but angiotensin IIderived
peptides were also shown to exert effects in such diseases. Moreover, it became obvious that
different cell and corresponding tissue types are characterized by their own renin-angiotensin system.
This system is composed of various peptidic derivatives of the precursor angiotensinogen. Those
angiotensinogen-derived peptides can be processed further by peptidases and can bind corresponding
receptors. Various clinical trials were initiated considering inhibition of the renin-angiotensin system at
different stages in cardiac injuries. Recently, a phase 3 trial using infused angiotensin II (LJPC-501) as
treatment option in catecholamine-resistent hypotension was established (ClinicalTrials.gov identifier
NCT02338843) although it might be that an influence of AngII-derived peptides is not considered. In
general, more intense research on AngII-derived peptides should result in novel strategies and therapeutic
options in treatment of cardiac and vascular injuries since these peptides exert actions by themselves,
some may interfere with AngII-mediated effects, and some can bind different receptors as well.
Consequently, they may also become new promising therapeutics in clinical settings in the future. This
short review introduces all currently known angiotensins at once, their production and role related to
cardiac and vascular injury, which immune cells show renin-angiotensin system components, and how
immune cells containing such components might be involved in such diseases as well.
Keywords: Angiotensins, angiotensin receptor, cardiac injury, cellular immunity, hypertension, renin-angiotensin system,
Rights & PermissionsPrintExport